

Reference:	FOI.15214.24
Subject:	Biologic and biosimilar products
Date of Request:	5 September 2024

Requested:

Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia]
- Adalimumab [Humira]
- Adalimumab Biosimilars
- Apremilast [Otezla]
- Baricitinib [Olumiant]
- Bimekizumab [Bimzelx]
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars
- Filgotinib [Jyseleca]
- Golimumab [Simponi]
- Guselkumab [Tremfya]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz]
- Risankizumab [Skyrizi]
- Rituximab [MabThera]
- Rituximab Biosimilars
- Sarilumab [Kevzara]
- Secukinumab [Cosentyx]
- Tocilizumab [Ro Actemra]
- Tocilizumab Biosimilars
- Tofacitinib [Xeljanz]
- Upadacitinib [Rinvoq]
- Ustekinumab [Stelara]
- Ustekinumab Biosimilar

Response:

1. Hywel Dda University Health Board (UHB) provides, within the table below, the number of Rheumatology patients, treated for any condition, with the listed medications, during the period 1 June to 31 August 2024.

Medication	Number
Abatacept [Orencia]	101
Adalimumab [Humira]	12
Adalimumab Biosimilars	257
Apremilast [Otezla]	28
Baricitinib [Olumiant]	59
Bimekizumab [Bimzelx]	*

Certolizumab [Cimzia]	38
Etanercept [Enbrel]	25
Etanercept Biosimilars	173
Filgotinib [Jyseleca]	*
Golimumab [Simponi]	30
Guselkumab [Tremfya]	0
Infliximab [Remicade]	0
Infliximab Biosimilars	18
Ixekizumab [Taltz]	7
Risankizumab [Skyrizi]	0
Rituximab [MabThera]	0
Rituximab Biosimilars	23
Sarilumab [Kevzara]	8
Secukinumab [Cosentyx]	48
Tocilizumab [Ro Actemra]	83
Tocilizumab Biosimilars	*
Tofacitinib [Xeljanz]	*
Upadacitinib [Rinvoq]	20
Ustekinumab [Stelara]	11
Ustekinumab Biosimilar	0

Where the figures in the table have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the FoIA. This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.